Clinical Trial Update: Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the efficacy and safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• FB825 (FB825)

Snippet

Sponsor: Oneness Biotech Co., Ltd. | Conditions: Atopic Dermatitis | Phase 2 | Status: RECRUITING